The challenge with DOAC detection
The use of direct oral anticoagulants (DOACs) is increasing. Unlike warfarin, the effects of DOACs cannot be reliably detected using standard coagulation testing and the rapid reversal of DOACs is complicated.
In trauma and acute care settings, knowing which anticoagulant a patient is taking — and how to reverse it — can be critical. Rapid DOAC detection enables clinicians to distinguish between agents quickly, supporting better-informed decisions and improved patient outcomes.
How does Doasense work?
The urine strip test detects DOACs (both factor Xa inhibitors and thrombin inhibitors) based on colour-changing chemical reactions that happen on the surface of the DOAC Dipstick test pads. Each dipstick test strip contains 4 test pads to detect:
-
direct oral thrombin inhibitors (dabigatran)
-
direct oral factor Xa inhibitors (apixaban, edoxaban and rivaroxaban)
-
urine colour (validation pad to help exclude abnormal urine colour that can affect results)
-
creatinine (validation pad to help exclude impaired renal function that can affect results).
Watch: DOASENSE in action — from urine sample to result
Where DOASENSE makes a difference ?
The determination of DOACs has long been limited to blood sampling approaches, with all their potential limitations, and a rapid assessment of the anticoagulant effect of non-vitamin K antagonist oral anticoagulants (Direct Oral AntiCoagulants – DOACs) by point-of-care testing (POCT) so far has been an unmet clinical need.
Rapid DOAC detection by point-of-care testing has long been an unmet clinical need. DOASENSE fills that gap — delivering specific, qualitative DOAC testing in urine that is easy to use, easy to interpret, reproducible, and patient-friendly.
Testing is particularly valuable in time-critical situations where DOAC status must be established rapidly.
-
Stroke — prior to thrombolytic therapy
-
Trauma and emergency procedures
-
Evaluation for venous thromboembolism
-
Spontaneous haemorrhage
-
General surgery or invasive procedures
-
Situations where medication history is unavailable
In each of these scenarios, the primary objective is confirming the absence — or presence — of DOACs before proceeding with treatment.
Features & Benefits
-
Single-use, point-of-care urine test strip — no laboratory required
-
Detects both factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) and thrombin inhibitors (dabigatran)
-
Results in minutes — designed for time-critical clinical settings
-
Easy to use and easy to interpret — minimal training required
-
Qualitative results with built-in validation pads for urine colour and creatinine
-
Reproducible and patient-friendly
-
Supported by the RCPA Quality Assurance Program (QAP)
-
Compatible with the DOASENSE reader for objective digital result interpretation
-
Suitable for emergency departments, stroke units, surgical settings, and trauma care
DOASENSE gives clinicians the confidence to act — fast, at the point of care, without waiting for laboratory results
Address
Haemoview Diagnostics
Suite 36 1b/47 Park Road
Milton Qld 4064
Australia
Phone
+61 (0)7 2111 6332
